{"classes":[{"categories":[{"measurements":[{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG000","spread":"NA","value":"6.200"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG004","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG005","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"11"}],"units":"Participants"}],"title":"Cycle 1/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54","value":"17.61"},{"groupId":"OG001","spread":"35","value":"13.22"},{"groupId":"OG002","spread":"38","value":"13.48"},{"groupId":"OG003","spread":"16","value":"17.52"},{"groupId":"OG004","spread":"78","value":"14.42"},{"groupId":"OG005","spread":"102","value":"9.445"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"title":"Cycle 1/Day15-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"116","value":"16.04"},{"groupId":"OG001","spread":"178","value":"11.04"},{"groupId":"OG002","spread":"31","value":"17.23"},{"groupId":"OG003","spread":"95","value":"11.93"},{"groupId":"OG004","spread":"32","value":"22.29"},{"groupId":"OG005","spread":"94","value":"13.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"title":"Cycle 2/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69","value":"26.76"},{"groupId":"OG001","spread":"54","value":"31.10"},{"groupId":"OG002","spread":"27","value":"17.77"},{"groupId":"OG003","spread":"20","value":"24.73"},{"groupId":"OG004","spread":"32","value":"29.11"},{"groupId":"OG005","spread":"10","value":"27.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"Cycle 4/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52","value":"30.03"},{"groupId":"OG001","spread":"59","value":"31.36"},{"groupId":"OG002","spread":"17","value":"18.87"},{"groupId":"OG003","spread":"1","value":"27.05"},{"groupId":"OG004","spread":"36","value":"33.12"},{"groupId":"OG005","spread":"8","value":"25.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Cycle 6/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48","value":"32.84"},{"groupId":"OG001","spread":"32","value":"36.98"},{"groupId":"OG002","spread":"26","value":"18.39"},{"groupId":"OG003","spread":"14","value":"35.08"},{"groupId":"OG004","spread":"29","value":"26.33"},{"groupId":"OG005","spread":"28","value":"39.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Cycle 10/Day1-0 Hour"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"11"}],"units":"Participants"}],"description":"Ctrough is steady-state pre-dose concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG000","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG001","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG002","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG003","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG004","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG005","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 1.0 mg/kg + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who had received at least one dose of study drug and who had at least one of the PK concentrations of interest for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycle 1, 2, 4, 6 and Cycle 10; Day 15 of Cycle 1 (non-dosing)","title":"Pre-Dose Observed Plasma Concentration (Ctrough) of Avelumab in Combination D","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}